Adverse events following immunization: is this time for the use of WHO causality assessment?

被引:21
作者
Tafuri, Silvio [1 ]
Gallone, Maria Serena [1 ]
Calabrese, Giulia [1 ]
Germinario, Cinzia [1 ]
机构
[1] Aldo Moro Univ Bari, Dept Biomed Sci & Human Oncol, I-70124 Bari, Italy
关键词
adverse events following immunization; causality assessment; Fluad case; postmarketing surveillance; WHO algorithm; VACCINE; SAFETY; AEFI; TOOL;
D O I
10.1586/14760584.2015.1029460
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In recent years, public health authorities in industrialized countries have noted an increase in the numbers of parents choosing not to have their children vaccinated and in the activities of 'antivaccination' movements. Doubts about vaccine safety and lack of surveillance of adverse events following immunization (AEFI) are the most frequent themes proposed by antivaccination movements. This editorial aims to critically analyze the use of AEFI assessment procedures among national health authorities and public health researchers. In fact, the WHO recommended and published a systematic and standardized causality assessment process for serious AEFI, providing a method for individual causality assessment to be used by staff of national immunization programs, regulatory authorities and pharmacovigilance or surveillance departments. The last update was published in March 2013 but to date, an Internet search reveals no information or reports on AEFI surveillance that uses the WHO AEFI causality assessment.
引用
收藏
页码:625 / 627
页数:3
相关论文
共 11 条
  • [1] Routine surveillance of adverse events following immunization as an important tool to monitor vaccine safety The two-years' experience of the Liguria Region, Italy
    Alicino, Cristiano
    Merlano, Caterina
    Zappettini, Simona
    Schiaffino, Sergio
    Della Luna, Giovanni
    Accardo, Cristina
    Gasparini, Roberto
    Durando, Paolo
    Icardi, Giancarlo
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (01) : 91 - 94
  • [2] [Anonymous], 2005, AID MEM ADV EV FOLL
  • [3] Post-marketing evaluation of the short term safety of COMVAX®
    Davis, RL
    Black, S
    Shinefield, H
    Mahoney, L
    Zavitkovsky, A
    Lewis, E
    Nikas, A
    Guess, H
    Coplan, P
    [J]. VACCINE, 2004, 22 (3-4) : 536 - 543
  • [4] Can the Brighton Collaboration case definitions be used to improve the quality of Adverse Event Following Immunization (AEFI) reporting? Anaphylaxis as a case study
    Gold, Michael S.
    Gidudu, Jane
    Erlewyn-Lajeunesse, Mich
    Law, Barbara
    [J]. VACCINE, 2010, 28 (28) : 4487 - 4498
  • [5] How society should respond to the risk of vaccine rejection
    Ropeik, David
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2013, 9 (08) : 1815 - 1818
  • [6] FLU VACCINATION DEATHS Deaths after Fluad flu vaccine and the epidemic of panic in Italy
    Signorelli, Carlo
    Odone, Anna
    Conversano, Michele
    Bonanni, Paolo
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2015, 350
  • [7] Spila-Alegiani Stefania, 2013, Recenti Progressi in Medicina, V104, P262, DOI 10.1701/1295.14327
  • [8] Addressing the anti-vaccination movement and the role of HCWs
    Tafuri, S.
    Gallone, M. S.
    Cappelli, M. G.
    Martinelli, D.
    Prato, R.
    Germinario, C.
    [J]. VACCINE, 2014, 32 (38) : 4860 - 4865
  • [9] Assessment of causality of individual adverse events following immunization (AEFI): A WHO tool for global use
    Tozzi, Alberto E.
    Asturias, Edwin J.
    Balakrishnan, Madhava Ram
    Halsey, Neal A.
    Law, Barbara
    Zuber, Patrick L. F.
    [J]. VACCINE, 2013, 31 (44) : 5041 - 5046
  • [10] WHO, GLOBAL VACC SAF CAUS